(NASDAQ: ZBIO) Zenas Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.33%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.58%.
Zenas Biopharma's earnings in 2025 is -$189,899,000.On average, 9 Wall Street analysts forecast ZBIO's earnings for 2025 to be -$202,134,267, with the lowest ZBIO earnings forecast at -$280,913,812, and the highest ZBIO earnings forecast at -$70,453,905. On average, 9 Wall Street analysts forecast ZBIO's earnings for 2026 to be -$232,022,827, with the lowest ZBIO earnings forecast at -$264,976,467, and the highest ZBIO earnings forecast at -$195,016,410.
In 2027, ZBIO is forecast to generate -$219,075,412 in earnings, with the lowest earnings forecast at -$290,382,816 and the highest earnings forecast at -$82,290,161.